Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · Real-Time Price · USD
0.3899
-0.0082 (-2.06%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Harvard Bioscience Revenue
In the year 2024, Harvard Bioscience had annual revenue of $94.14M, down -16.14%. Harvard Bioscience had revenue of $24.56M in the quarter ending December 31, 2024, a decrease of -12.78%.
Revenue (ttm)
$94.14M
Revenue Growth
-16.14%
P/S Ratio
0.18
Revenue / Employee
$265,169
Employees
355
Market Cap
17.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 94.14M | -18.12M | -16.14% |
| Dec 31, 2023 | 112.25M | -1.09M | -0.96% |
| Dec 31, 2022 | 113.34M | -5.57M | -4.68% |
| Dec 31, 2021 | 118.90M | 16.80M | 16.46% |
| Dec 31, 2020 | 102.10M | -14.08M | -12.12% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
HBIO News
- 14 days ago - Harvard Bioscience Announces CFO Transition - GlobeNewsWire
- 6 weeks ago - Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025 - GlobeNewsWire
- 6 weeks ago - Harvard Bioscience, Inc. (HBIO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting - GlobeNewsWire
- 2 months ago - Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET - GlobeNewsWire
- 3 months ago - Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference - GlobeNewsWire
- 5 months ago - Harvard Bioscience, Inc. (HBIO) Q3 2024 Earnings Call Transcript - Seeking Alpha